Table 4. Treatment-related adverse reactions with an incidence of ≥2% in both groups.
| Symptoms | Megestrol group (n=60), n (%) | Control group (n=60), n (%) | χ2 | P* | |||||
|---|---|---|---|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 1 | Grade 2 | Grade 3 | ||||
| Fatigue | 7 (11.7) | 0 (0) | 0 (0) | 3 (3.5) | 0 (0) | 0 (0) | 1.745 | 0.186 | |
| Constipation | 10 (16.7) | 1 (1.7) | 0 (0) | 5 (8.3) | 0 (0) | 0 (0) | 2.596 | 0.107 | |
| Hiccup | 1 (1.7) | 0 (0) | 0 (0) | 2 (3.3) | 0 (0) | 0 (0) | 0.342 | 0.559 | |
| Vaginal bleeding | 3 (5.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3.077 | 0.079 | |
| Pain | 5 (8.3) | 0 (0) | 0 (0) | 3 (5.0) | 3 (5.0) | 0 (0) | 0.100 | 0.752 | |
| Abnormal liver function | 9 (15.0) | 2 (3.3) | 0 (0) | 19 (31.7) | 1 (1.7) | 0 (0) | 3.523 | 0.061 | |
| Abnormal renal function | 4 (6.7) | 0 (0) | 0 (0) | 4 (6.7) | 0 (0) | 0 (0) | 0.000 | 1.000 | |
| Hypokalemia | 3 (5.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3.077 | 0.079 | |
| Hyperkalemia | 1 (1.7) | 0 (0) | 0 (0) | 2 (3.3) | 0 (0) | 0 (0) | 0.342 | 0.559 | |
| Leukocyte elevation | 4 (6.7) | 0 (0) | 0 (0) | 4 (6.7) | 0 (0) | 0 (0) | 0.000 | 1.000 | |
| Leukopenia | 3 (5.0) | 5 (8.3) | 0 (0) | 10 (16.7) | 6 (10.0) | 1 (1.7) | 4.093 | 0.043 | |
| Thrombocytopenia | 1 (1.7) | 1 (1.7) | 0 (0) | 1 (1.7) | 1 (1.7) | 0 (0) | 0.000 | 1.000 | |
| Anemia | 11 (18.3) | 9 (15.0) | 1 (1.7) | 5 (8.3) | 7 (11.7) | 1 (1.7) | 2.627 | 0.105 | |
*, the P value was tested using the Pearson c2 test.